Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2018 at "mAbs"
DOI: 10.1080/19420862.2018.1433974
Abstract: ABSTRACT Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization and mortality in young children. Protective therapy options are limited. Currently, palivizumab, a monoclonal IgG1 antibody, is the only licensed drug for RSV… read more here.
Keywords: iga; human iga; infection; palivizumab motavizumab ... See more keywords